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Poster Session-II 131CB and ex vivo CB as well as peripheral blood mononuclear cells
(PBMC) as controls. T cell receptor spectratyping was performed
before and after expansion with aim to determine usage of different
TCR Vbetas.
Results:T cells expanded with a median of 148-fold over a period
of 8–11 days. Expanded preparations contained 99% of CD31 cells
without signs for significant expansion of CD191 or CD3-/CD561
cells. CD4/CD8 ratio of expanded T cells was not altered signifi-
cantly when compared to CB ex vivo (a mean of 1,7 to 2,02, respec-
tively). The majority of T cells were positive for ab T cell receptor
(93%). Up to 85% of expanded T cells were CD251, 3% of
CD31 fraction were CD251/FoxP31. Expanded T cells, when
stimulated with CD3-beads, produced IL-2, IFN-g, TNF-a in
a cell to bead ratio in a dose-dependant manner at higher levels, com-
paraed to peripheral T cells and CB ex vivo T cells. TCR spectratyp-
ing has shown a polyclonal pattern of TCR Vbeta-gene usage in the
expanded T cell pool.
Conclusions: We have successfully set up a clinically feasible sys-
tem of T cell expansion for use as DLI after CBT. The expansion
procedure has not introduced major phenotypic changes when com-
pared to CB cells ex vivo. Expanded cells are functional in terms of
cytokine production and display no oligoclonal pattern of TCR us-
age. Expanded CB T lymphocytes may serve as a possibility for DLI
after CBT.365
GRAFT-VERSUS-HOST REACTIONS TARGET HEMATOLYMPHOID ORGANS
LEADING TO ALTERATIONS IN HEMATOPOIETIC RECONSTITUTION AND
DYSFUNCTIONAL IMMUNITY
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The pathophysiology of chronic (c) Graft-versus-Host Disease
(GVHD) is poorly understood. The protean nature of the syn-
drome suggests more complex mechanisms than pure T cell (TC)
effects. We analyzed cellular infiltrates of hematolymphoid tissues
(bone marrow (BM), spleen, lymph nodes (LN), thymus, liver) after
hematopoietic cell transplantation (HCT) in 3 minor-mismatched
mouse models of GVHD. Myeloablated BALB.B (H2b), BALB/c
(H2d), and BALB.K (H2k) mice were given purified hematopoietic
stem cells 1 splenocytes (SP) from C57BL/6 (B6), B10.D2, or
AKR/J donors, respectively. BALB.B recipients developed acute
and chronic GVHD. BALB/c mice showed skin lesions on ears
and tail, which resolved by d50, but no systemic or late symptoms.
Despite a lower SP dose BALB.K hosts developed fulminant
GVHD. Differences in type and kinetics of cellular infiltration of
organs were observed between the strains. In all 3 models BM
was a major site of donor (do) TC infiltration early post-HCT.
While B cell (BC) reconsititution was severely delayed BALB.B
BM contained 50% doTC, which were in 60% CD81 (effector
memory (EM) phenotype), and H60 tetramer-reactive in up to
24%. At a low level doTC persisted long-term in the BM.
BALB/c recipients of B10.D2 grafts had better BC regeneration
and less infiltrating doTC (40%). The latter were CD4/8 balanced
and normalized promptly (d50 \3%). In contrast, BALB.K mice
given AKR/J grafts, had prominent CD4 (EM) doTC infiltrates.
The liver was a main target of GVH in BALB.B recipients: 14d
post-HCT liver MNC contained 60–80% doTC, 30% reactive to
H60. Low levels of infiltration were observed long-term. In
BALB/c livers Mac1/Gr11 cells predominated (\60%), while
doTC infiltration was less severe and resolved completely. BALB.K
livers contained 80% doTC, mostly CD41. Thymuses, spleen
and LN of BALB.B and K recipients were hypoplastic, hypocellular
and infiltrated by doTC with a decreased CD4/811 fraction.
BALB.K LN had predominantly CD4 doTC and lacked BC, while
BALB.B LN contained CD8.CD4. Thymuses, spleen and LN of
BALB/c recipients normalized after some initial doTC infiltration.
In conclusion, hematolymphoid organs can be GVH targets, which
is associated with impaired hematopoietic and immune reconstitu-
tion. Damage of these tissues may disturb normal immunity, and
via dysfunctional immune education indirectly contribute to auto-
immune-like phenomena as seen in chronic GVHD.366
FEASABILITY OF EXTRACORPOREAL PHOTOPHERESIS IN MANAGING PA-
TIENTS WITH BRONCHIOLITIS OBLITERANS FOLLOWING ALLOGENEIC
STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE
Rome, A.M., Toor, A.A., Chung, H., Roseff, S.D., Edwards, R.,
Lamberta, J., Anderson, J., Candler, K., McCarty, J.M. Virginia Com-
monwealth University, Richmond, VA
Introduction: Bronchiolitis obliterans (BO) is a serious, often fa-
tal complication of allogeneic stem cell transplantation (SCT). Most
patients do not respond to conventional immunosuppressive ther-
apy. We retrospectively reviewed records of patients with BO treated
with extracorporeal photopheresis (ECP), given its efficacy in man-
aging chronic corticosteroid refractory cutaneous, oral, and hepatic
graft versus host disease (GVHD).
Patients and Methods: Forty two patients were treated at our
center for chronic GVHD with ECP from 2003–2007. Thirteen pa-
tients (31%) met diagnostic criteria for BO defined as the presence of
pulmonary symptoms, hypoxemia and one of the following 1) de-
crease in FEV1 by.20% or 2) air-trapping, small airway thickening
or bronchiectasis on lung CT without evidence of an infection. ECP
was performed on 2 consecutive days every 2 weeks for the first 4
months and less frequently thereafter.
Results: Nine of thirteen patients met criteria due to decrease in
FEV1 and lung changes on CT; 4 due to radiographic findings alone.
ECP was initiated at a median of 954 days (range, 173–2122 days) af-
ter allogeneic SCT (11 matched related donors, 2 unrelated donors).
All but one patient had failed prior corticosteroid-based immuno-
suppressive therapy. With a median follow-up of 782 days from di-
agnosis of BO, 11/13 (85%) of the patients are alive. Seven of
thirteen (54%) patients had a 50% decrease in steroid dosage without
deterioration of pulmonary function; 3/13 (23%) patients had im-
provement of radiographic abnormalities; 4/7 (57%) patients with
oxygen requirements prior to initiation of ECP were completely ti-
trated off oxygen. No patients had a decline in pulmonary function
tests despite steroid withdrawal. Only 3 patients experienced grade
III or higher adverse events related to the indwelling catheter (3 in-
fectious, 1 bleeding and 2 thromboses). Two of thirteen patients
died, one due to progression of BO and 1 from pneumonia. Our ob-
served survival rate of 85% in patients with BO is in contrast to the
44–73% survival rate noted in prior studies using treatment with
conventional immunosuppressive therapy.
Conclusion: In this retrospective study, we demonstrate the fea-
sibility of using ECP to manage BO occurring after allogeneic
SCT. ECP should be considered as early second-line therapy in pa-
tients developing BO following SCT; however, further study is war-
ranted to confirm these results.367
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INTENSITY CONDITIONING (RIC-HCT)
Rosch, P.1, Aigner, T.2, Franke, G.1, Lange, T.1, Niederwieser, D.1,
Basara, N.1 1University of Leipzig, Leipzig, Germany; 2University of
Leipzig, Leipzig, Germany
Objectives: Acute GvHD remains a severe complication after
RIC-HCT. We report here the predictive value of bone marrow
and intestinal eosinophilia in patients transplanted from 1999 to
2005 by using RIC HCT.
Patients andmethods:One hundred and fifteen patients (55 fe-
male) with haematological malignancies with the median age of 59
years (range 21 to 75) were treated with RIC-HCT for AML (n 5
76), ALL (n 5 7), CML (n 5 13) and MDS (n 5 19). Condition-
ing regimen consisted of fludarabine at day -4 to -2 and 2 Gy total
body irradiation at day 0 followed by the infusion of HCT of an
related (n 5 30), allele matched unrelated (n 5 76) or mismatched
(n 5 9) donor and treatment with MMF and CSA. Bone marrow
and peripheral blood evaluation was performed before and on day
128 after RIC-SCT; Eosinophilia was graduated from 0 to 4. Sys-
tematic colon and/or duodenal biopsies have been performed im-
mediately after first symptoms of gut GvHD. Histological criteria
of gut GvHD were assessed and tissue eosinophils analysed within
the lamina propria and lamina submucosa. The density of
132 Poster Session-IIeosinophils in bone marrow, gut and peripheral blood were ana-
lysed by using SPSS.
Results: The incidence of acute GvHD was 51% (36% grade 1,
27% grade 2, 15% grade 3 and 22% grade 4 out of it). One organ
aGVHD was diagnosed in 42 (skin n 5 36, gut n 5 4, liver n 5 2),
two-organ aGvHD in 10 and tree-organ aGvHD in 7 patients.
The density of bone marrow eosinophils was increased after RIC-
SCT in comparison to before it (6% vs 3.4%, p\0.001, respectively).
Bone marrow eosinophilia after RIC-SCT was found in 66% of pa-
tients with aGvHD and was a significant predictive factor (p\0.03)
for developing aGvHD. However, eosinophil density did not corre-
lated with aGvHD severity. Peripheral blood eosinophilia was not
predictive for developing aGvHD. Intestinal eosinophils were found
in 15 of 20 patients with clinical signs of gut GvHD, which has been
consequently histologically proven in 13 patients (87%, p\0.02).
The degranulation of eosinophils, determined by using anti-MBP
was present in all patients with gut aGvHD.
Conclusions: Both gastrointestinal tract and bone marrow tissue
eosinophilia after RIC-SCT predict aGvHD. In addition, gut eosin-
ophil density and degranulation were increased in patients with
higher grades of aGvHD thus indicating their role as a biological
marker of GvHD. To our knowledge this is the first study showing
that tissue eosinophil density might be a predictive marker for
aGvHD after RIC-SCT.368
IMMUNOMODULATORY EFFECTS OF VITAMIN D: IMPLICATIONS FOR THE
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Allogeneic transplantation is uniquely curative for some patients
with hematologic malignancies. However, morbidity and mortality
due to graft versus host disease remain substantial. Persistence of
host dendritic cells (DCs) in the early post transplant period plays
a role in the activation of alloreactive lymphocytes and the risk of
GVHD. A focus of research involves the manipulation of DC re-
covery post-transplant to minimize activation of alloreactive lym-
phocytes while preserving the graft versus disease effect. Vitamin
D is a hormone involved in bone metabolism. More recently, vi-
tamin D has been shown to have immunomodulatory effects. We
evaluated the effect of vitamin D on the phenotypic and functional
characteristics of DC and T cell populations. Peripheral blood
mononuclear cells were isolated from leukopaks obtained from
normal donors. DCs were generated by culturing the monocyte
enriched adherent fraction with GM-CSF and IL-4 for 5 days,
followed by TNFa for 48 hours. DCs were generated in the
presence and absence of 10nM of 1,25 hydroxyvitamin D. Mean
expression of the costimulatory molecule CD80 and the matura-
tion marker CD83 decreased from 60% to 37% and 53% to
27% respectively in the presence of vitamin D (N 5 3). To assess
the effect of vitamin D on the functional potency of DCs as anti-
gen presenting cells, the capacity of DCs to stimulate allogeneic
T cell proliferation in the presence of vitamin D was determined.
Mature DCs were cultured with allogeneic T cells at a ratio of
1:10. After 5 days, cocultures were pulsed with tritiated thymidine
overnight. The addition of vitamin D resulted in a blunted T cell
proliferative response, with mean SI that decreased from 13 to 5
(n 5 10). Similarly, the addition of vitamin D to a coculture of
DCs and autologous T cells resulted in a 50% reduction in the
T cell proliferative response to tetanus toxoid, a recall antigen.
In addition, T cells stimulated by allogeneic DCs in the presence
of vitamin D were polarized to secrete Th2 cytokines. The pres-
ence of vitamin D did not induce FOXP3 expressing regulatory
T cell populations. These data suggest that exposure to vitamin
D exerts a tolerizing influence on T cells mediated by its impact
on antigen presenting cells. Vitamin D may therefore have a role
in the prevention and treatment of graft versus host disease.
A clinical trial evaluating the use of vitamin D in the early post-
transplant period for the prevention of GVHD is planned.369
ALLOGENEIC VERSUS AUTOLOGOUS STEM CELL TRANSPLANTATION
(SCT) FOR FOLLICULAR LYMPHOMA (FL). THE JAMES COMPREHENSIVE
CANCER CENTER EXPERIENCE
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Majority of the reported studies comparing allogeneic versus au-
tologous SCT in patients with FL have short follow-up (median 5
or\5-yrs). Patients with histologically confirmed FL (n 5 117) un-
dergoing SCT between 1985 and 2007 were eligible for this study.
Patient characteristics including age, stage, LDH, number of prior
therapies, remission status at SCT [CR, PR, untreated relapse
(REL), refractory (REF)], and transplant characteristics were re-
corded. The median age was 49 years (range 23–71). 36 patients un-
derwent allogeneic SCT (including 10 patients receiving reduced
intensity conditioning), while 81 patients underwent autologous
SCT. The median number of prior treatments for autologous and al-
logeneic SCT groups were 2 (range 1–5) and 3 (range 1–7) respec-
tively. Median follow-up is 7-years. 5-year OS following
autologous SCT for patients in CR1/PR1, CR.1/PR.1 and re-
lapsed or refractory disease was 79%, 71% and 53% respectively.
The respective OS for allogeneic SCT was 51%, 75%, and 49%. Re-
lapse rates were lower following allogeneic SCT versus autologous
SCT at 27% versus 55% respectively. 5 year progression free survival
(PFS) was higher following allogeneic SCT at 46% versus 38%.
Higher non-relapse mortality (NRM) with allogeneic SCT (25%
versus 11%) resulted in a 5 year OS favoring autologous SCT
(67% versus 57%). With prolonged follow-up a plateau was seen
in allogeneic SCT curve at around 3-yrs, while autologous SCT pa-
tients continued to experience events. Hence the estimates of 10-yr
OS for allogeneic SCT patients was 57% (unchanged from 5-yr
OS), compared to 48% for autologous SCT. Our study shows that
although the early results of allogeneic SCT (mostly with myeloabla-
tive conditioning) are negatively impacted with associated high
NRM, it produces durable remissions, with eventual appearance of
trends of improved survival with prolonged follow-up.370
PHARMACOKINETICS (PK) OF IV AND PO MYCOPHENOLATE MOFETIL
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Children undergoing AlloSCT exhibit higher MMF dose require-
ments and significant interpatient variability in mycophenolic acid
(MPA) PK (Jacobson P et al, Ped 2008). The objective of this study
is to evaluate effects of age and conditioning intensity on the PK
of MMF in pediatric AlloSCT recipients. From 1/04-5/08 we en-
rolled 38 pts: med age 8 yrs (0.33–16); M:F 5 20:18; 22/16 malig-
nant/non; 17/21 myeloablative (MA)/non-ablative (NMA); 16/22
related/unrelated. Cohort 1 (\6 yrs) n 5 14; 2 (6–12 yrs) n 5 10;
3 (12–16 yrs) n 5 12. GVHD prophylaxis: tacrolimus Day –1 (5–
20 ng/mL) and MMF 900 mg/m2 IV Q6H starting on Day 11,
then converted to PO (same dose) after Day 114. MPA serum sam-
ples were drawn on Days11,17,114 (IV phase) and twice between
Day 145-1100 (PO phase) at hour 0, 0.5, 1, 2, 3, 4, 6 post-dose.
MPA plasma concentrations were determined by reverse-phase
HPLC and LC/MS/MS. Non-compartmental PK analysis of total
MPA was performed. Median time to myeloid and platelet engraft-
ment was 18 and 31 d, respectively. KM probability of Grade II-
IV acute GVHD (aGVHD) and extensive chronic GVHD
